

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India



## AGENDA AT A GLANCE

## Key Speakers Include



**KIRAN MARTHAK**  
Directors-Mgmt, **Lambda** (Vice Chairman of Medical  
Committee, **Indian Drug Manufacturers' Association**)



**RAJENDRA SANGHAVI**  
Sr. Consulting Clinician & Chairman - Medical  
Committee, **Indian Drug Manufacturers' Association**



**PRASANNA BANGALE**  
Vice President & Head, Global Regulatory Affairs  
**Alembic Pharmaceuticals**



**OMPRAKASH S. SADHWANI**  
Former Joint Commissioner and controlling  
Authority, **FDA (Maharashtra state)**



**DEEPA ARORA**  
Director  
**CLINEXEL Life Sciences**



**GIRISH PARHATE**  
Vice President - Regulatory Affairs, India  
**Dr. Reddy's Laboratories**



**MAHESH ABHYANKAR**  
Vice President - Medical and L and D  
**USV**



**ROHIT ARORA**  
Medical Director  
**Eli Lilly**



**S.R. SALUNKHE**  
Former Assistant commissioner  
**FDA Maharashtra**



**AVINASH R. KAKADE**  
SGM, Global Head - Pharmacovigilance  
**Lupin Global**



**MANISH MAHAJAN**  
Head- Medical Affairs  
**Cadila Healthcare Ltd (BU- Biologics)**



**AMITA BHAWE**  
Head Regulatory Affairs GDD India  
**Novartis**



**PRAVIN GHADGE**  
Head of Clinical Research Services  
**Reliance Life Sciences**



**CHIRAG TELI**  
Head of Medical Services  
**Alkem Laboratories**



**RANJIT BARSHIKAR**  
CEO - QbD International, United Nations  
Adviser, Member Editorial Board Journal of  
Generic Medicines, England



**MILIND ANTANI**  
Leader, Pharma and Healthcare  
**Nishith Desai Associates**



**SAKHARAM GARALE**  
Head South-East Asia Operations ACMA &  
Managing Partner, **RENOVARE Healthcare  
Solutions**



**ANISH DESAI**  
Director  
**IntelliMed Healthcare Solutions**



**SHIRAZ KANDAWALLA**  
Associate Director - Regulatory Affairs  
**Abbott**



**SEEMA GURBANI**  
Offering Lead- Medical Writing and Medical Affairs  
[LifeSciences- North America Region], **Tata  
Consultancy Services**



**VISHWAS SOVANI**  
Founder Director  
**Pharmawisdom**



**KAVYA KADAM**  
Consultant Global Clinical Trials

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Ponur  
Chennai - 600 116  
India

+91 44 42108101

info@virtueinsight.com

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

"Good for getting knowledge & understand current  
requirements for Industry"

Sr. Executive - RA, USV

## AGENDA AT A GLANCE

### Key Speakers Include



**ANANT PATIL**  
Asst Professor Department of Pharmacology  
Dr DY Patil Medical College



**HITENDRA BHATIA**  
Manager Regulatory Affairs  
Procter & Gamble Health

#### WHO ATTENDS?

**30+**  
Speakers

**70%**  
Pharma  
/ Biotech

**3+**  
Hours of  
Networking

**1**  
Day

**1**  
Golden  
Opportunity

[www.virtueinsight.com](http://www.virtueinsight.com)

#### KNOWLEDGE PARTNER

**Nishith Desai** Associates  
LEGAL AND TAX COUNSELING WORLDWIDE

#### SUPPORTED BY



Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101

[info@virtueinsight.com](mailto:info@virtueinsight.com)

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

"This was one of the conference that I attended had many topics of high relevance and open environment for discussion."

Sr. Manager - Global RA, Abbott

## AGENDA AT A GLANCE

### CONFERENCE INTRODUCTION

India is an attractive target for pharmaceutical companies and other clinical research providers. India promises access to more patients, in greater concentrations, than most other markets, as well as the opportunity to establish trials with treatment-naïve patients. India is a pool of diverse population base of more than 1.2 billion and is a home for a numerous diseases, Institutions and hub of contract manufacturers and researchers. Indian economy stand as the third largest based on the Purchasing Power Parity (PPP) and in terms of globally eleventh largest by nominal Gross Domestic Product (GDP). India is today one of the top emerging markets in the global pharmaceutical scene. The sector is highly knowledge based and its steady growth is positively affecting the Indian economy. The organised nature of the Indian pharmaceutical industry is attracting several companies that are finding it viable to increase their operations in the country. Further, India is home to about 10,500 manufacturing units and over 3,000 pharma companies. India exports all forms of pharmaceuticals from APIs to formulations, both in modern medicine and traditional Indian medicines. These figures have given rise to legislation seeking to improve access to medicines and the Indian government has recently taken unprecedented steps to improve its healthcare and regulatory system

**3rd Annual Pharma Regulatory Summit 2020** brings together leading global pharmaceutical industry professionals and regulators to share their insights on technologies, approaches, and solutions that will drive innovation and quality for the medicines delivered to patients worldwide. This interactive setting with expert-led regulatory and industry presentations and forums will ensure pharmaceutical industry professionals are well-prepared to develop and apply innovative solutions in today's global regulatory environment.

### KEY THEMES DISCUSSED

- Understanding the current regulatory framework
- Overcoming key challenges with product registration in India
- Determining best strategies for the application and approval of variations in India
- Outlining key requirements for filing variations in India
- Current regulatory compliance issues and opportunities for regulatory authorities and industry experts
- Overviewing the current regulatory landscape in 2020 & 2021
- Clinical evidence for regulatory purposes
- Purpose of the public workshop. Bringing the team of investors together to discuss key issues for the use of randomized designs
- Exploring the current biosimilar legal landscape
- Studying the latest battles occurring in the biosimilar domain
- Developing scenarios for the Asian pharma market
- Top line innovation trends and implications
- The regulatory reform of India and its effect on the pharmaceutical industry
- Discussing the requisite collaboration between pharmaceutical companies and government agencies
- Digital regulatory innovation and advanced technology
- Insight into the future of regulatory issues in the digital world and how businesses need to adopt advanced technology to challenge the traditional way in which regulatory data and application processes are managed
- Practical guidance for drug registration compliance in India
- Navigating the best regulatory pathway for successful drug approval
- Be part of a major networking opportunity

### WHY SHOULD YOU ATTEND?

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

### WHY EXHIBIT?

- Make Sales
- Debut new products
- Profile your brand
- Meet new business partners
- Develop key relationships
- Educate pharma and biotech companies



### WHO SHOULD ATTEND AND WHO YOU'LL MEET

This conference is specifically designed for pharma, biotech, CRO's, Government and Regulators, Hospitals/Trial Sites, Technology & Solution Providers and medical device professionals responsible for:

Regulatory Affairs, Regulatory Writing/Medical Writing/Publishing/Information/Submissions, Document and eRecords Management, Business Operations/Processing, Labelling, Clinical Trials Management/Data, Clinical Data, Outsourcing/Clinical Outsourcing/Vendor Management, Product Development, Quality Assurance/Quality Control, Patient recruitment companies, Government- Department of health, Non-profit organizations/ Association, Consultants

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101

info@virtueinsight.com

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

"Very good speakers and it was a good knowledge expansion.  
Arrangement was good."

Regulatory Affairs officer, Fresenius Kabi India

## AGENDA AT A GLANCE

### DAY ONE - 12th March 2020

08:30 - Coffee and registration - An opportunity to meet  
and to network with your conference colleagues.

09:20 - Chairperson opening remarks

**RANJIT BARSHIKAR**  
CEO - QbD International, United Nations Adviser  
Member Editorial Board Journal of Generic Medicines,  
England

### MARKET OVERVIEW & ANALYSIS

09:30 - FDCs - Boon or Bane

- FDCs are flagship of India's formulations.
- Ridiculing FDCs sans sound medical basis will spell inconvenience for patients and compromise outcomes in chronic therapies.
- Differentiating between those justifiable and those scientifically irrational holds the key to future of FDCs.
- Governing rational FDCs prescribing is more a regulatory and a medical challenge rather than implicate the healthcare industry.
- Unbiased SOPs required to ensure necessary FDCs for patient's welfare.

**RAJENDRA SANGHAVI**  
Sr. Consulting Clinician & Chairman - Medical Committee  
Indian Drug Manufacturers' Association (IDMA)

10:00 - Upsurge of Real World Evidence and Regulatory  
Decision Making

**MAHESH ABHYANKAR**  
Vice President - Medical and L and D  
USV

10:30 - Morning Coffee/Tea & Discussion

### CHALLENGES & OPPORTUNITIES

10:50 - DISCUSSION WITH EXPERTS: Current  
regulatory compliance issues and opportunities for  
regulatory authorities and industry experts

- Overviewing the current regulatory landscape in 2020  
& 2021

- How pharmaceutical companies stay ahead of these changes?
- How digital applications conflict with the legal and regulatory landscape?
- Clear specifications for registration and regulation of pharmaceutical products and medical devices in India
- Challenges in securing authorization from authorities for medical devices
- Regulations on trial guidelines, devices, safety, approval and market access
- Discussing strategies about global marketing campaigns for biosimilar products

Moderator:

**RANJIT BARSHIKAR**  
CEO - QbD International, United Nations Adviser  
Member Editorial Board Journal of Generic Medicines,  
England

Panellists:

**AVINASH R. KAKADE**  
SGM, Global Head - Pharmacovigilance  
Lupin Global

**ROHIT ARORA**  
Medical Director  
Eli Lilly

**OMPRAKASH S. SADHWANI**  
Former Joint Commissioner and controlling Authority  
Food and Drug Administration (Maharashtra state)

**SAKHARAM GARALE**  
Head South-East Asia Operations ACMA & Managing  
Partner, RENOVARE Healthcare Solutions

**KAVYA KADAM**  
Consultant Global Clinical Trials

11:30 - DISCUSSION WITH EXPERTS: Clinical evidence  
for regulatory purposes

- Using randomized clinical trials for regulatory purposes to generate real-world evidence
- Purpose of the public workshop. Bringing the team of investors together to discuss key issues for the use of randomized designs
- Explore key considerations for using randomized designs of clinical trials and real-world data (RWD) to generate RWE, especially in clinical care settings
- Possible integration of clinical trials into the health care system through the use of randomized designs to generate RWE for regulatory applications

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101

info@virtueinsight.com

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

"Very well organised conference. Presentations was crisp and informative. Over all very knowledgeable."

Senior Manager, Sun Pharma Advanced  
Research Center

## AGENDA AT A GLANCE

### DAY ONE - 12th March 2020

- Use of real-world evidence to support medical device regulatory decision-making
- Data collected from other sources, such as mobile devices, that can inform about health status

#### Moderator:

**S.R.SALUNKHE**  
Former Assistant commissioner  
FDA Maharashtra

#### Panellists:

**DEEPA ARORA**  
Director  
CLINEXEL Life Sciences

**ANISH DESAI**  
Director  
IntelliMed Healthcare Solutions

**CHIRAG TELI**  
Head of Medical Services  
Alkem Laboratories

**ANANT PATIL**  
Asst Professor Department of Pharmacology, Dr DY Patil  
Medical College

.....

#### 12:10 - Clinical and regulatory considerations of Drug Device Combination Products- Human factors/ usability testing studies, PMS plan, PMCF Plan

- Relevant US and EU regulations for Drug Device combinations
- Relationship of Human Factor and Major Clinical Studies of combination Products
- Considerations for Submission of Combination Products Human Factors Study data
- Tailored HFE Processes
- Key aspects of Developing cost effective, efficient PMS and PMCF Plan

**DEEPA ARORA**  
Director  
CLINEXEL Life Sciences

.....

#### 12:40 - Networking luncheon

.....

#### Afternoon Chair Person

.....

#### 13:50 - Understanding the current regulatory framework

- Current regulatory environment and any recent changes
- Overcoming key challenges with product registration in India
- Best strategies for product registration
- Outlining major legal challenges currently being faced

**SAKHARAM GARALE**  
Head South-East Asia Operations ACMA & Managing  
Partner, RENOVARE Healthcare Solutions

.....

#### 14:20 - DISCUSSION WITH EXPERTS: Clinical Regulatory Medical Writing - Ensuring regulatory standards are met in structured and manageable timeline

- Regulatory medical writer: More than a writer, an expert
- Establish patient anonymization and de-identification processes that satisfy transparency requirements while preserving the integrity of the clinical research
- Increase the quality and speed of protocol writing by leveraging various templates
- Analyze the benefits of having a medical writer as a strategic partner in document preparation and submission planning
- Create models for working with vendors/contractors that can be adapted for changing program and document needs
- Develop effective onboarding and mentoring programs that will allow you to recruit millennials and train the next generation of medical writers

#### Moderator:

**VISHWAS SOVANI**  
Founder Director  
Pharmawisdom

#### Panellists:

**KIRAN MARTHAK**  
Directors - Management, Lambda (Vice Chairman of the  
Medical Committee), Indian Drug Manufacturers'  
Association (IDMA)

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101  
info@virtueinsight.com

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

"Informative, got insights of current and fast changing scenarios."

Associate Regulatory Affairs, Abbot

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

## AGENDA AT A GLANCE

### DAY ONE - 12th March 2020

#### PRAVIN GHADGE

Head of Clinical Research Services  
Reliance Life Sciences

#### SEEMA GURBANI

Offering Lead- Medical Writing and Medical Affairs  
[LifeSciences- North America Region], Tata Consultancy  
Services

.....

15:10 - Afternoon Tea/Coffee

.....

15:30 - Biosimilar and Healthcare Care Professionals:  
Need Gaps

- HCP perceptions of Biosimilars
- HCP views: Evidences on Biosimilars
- Barriers and Facilitators to prescribe Biosimilars
- Patients perceptions to Biosimilars

#### MANISH MAHAJAN

Head- Medical Affairs  
Cadila Healthcare (BU- Biologics)

.....

16:00 - DISCUSSION WITH EXPERTS: The Pharma  
Regulations in India: The Good, The Bad,  
The Ugly

- Pharmaceutical regulatory landscape in India
- Are regulations becoming strangulations for Pharma sector in India?
- Putting best foot forward with current regulations
- Pharma Regulatory Maize in India: Can there be winner?
- Navigating Regulatory Pathways to Address unmet medical needs
- Real World Evidence: Improve your regulatory intelligence for better business outcomes
- The Indian pharmaceutical industry - the way forward

Moderator:

#### MILIND ANTANI

Leader, Pharma and Healthcare  
Nishith Desai Associates

Panellists:

#### PRASANNA BANGALE

Vice President & Head - Global Regulatory Affairs  
Alembic Pharmaceuticalst

#### GIRISH PARHATE

Vice President - Regulatory Affairs, India  
Dr. Reddy's Laboratories

#### SHIRAZ KANDAWALLA

Associate Director - Regulatory Affairs  
Abbott

#### AMITA BHAVE

Head Regulatory Affairs GDD India  
Novartis

#### HITENDRA BHATIA

Manager Regulatory Affairs  
Procter & Gamble Health

.....

16:50 - Chairperson's closing remarks and end of  
conference

.....

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101

info@virtueinsight.com

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"


"Its a good conference covering all Corner of regulatory."

Sr. Scientist, Inventia Healthcare

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

## AGENDA AT A GLANCE

**FLOOR PLAN** - Book your stalls now before they run out !!!



1

4

7

2

5

8

3

6

**Note :-** The floorplan is subject to change at the discretion of the organisers.

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101

info@virtueinsight.com

# 3rd Annual Pharma Regulatory Summit 2020

"Understanding recent regulatory developments to explore innovative strategies"

12th March 2020, Kohinoor Continental  
Hotel, Mumbai, India

"The event has been organised very well, with a smooth flow of the full programme. Excellent selection of relevant topics and knowledgeable and expert presenters / Panelists."

Team Leader, Novo Nordisk

## REGISTER ONLINE :

Link : <https://www.bookmytrainings.com/catalogue/event/73612-3rd-annual-pharma-regulatory-summit-2020>

For Multiple Bookings - Photocopy this form and send it to [bookings@virtueinsight.com](mailto:bookings@virtueinsight.com)

## AGENDA AT A GLANCE

## REGISTRATION FORM

### RESERVATION PRICING:

#### Standard Rate

Cost per delegate - Fee: INR 15,000 + GST(18%)

#### Discounted Rate for Bulk Booking of More Than 5 Delegates

Please email us at [bookings@virtueinsight.com](mailto:bookings@virtueinsight.com)

#### Registration Form Details:

Forename .....Surname .....

Job Title .....

Company .....

GST No (If Applicable) .....

Official Contact Number .....

Address .....

Country .....Postcode.....

Phone .....Fax .....

Email .....

I confirm that I have read & agree to the terms and conditions of booking..... (Please Tick)

Signature .....

#### Methods of Payments:



**By Cheque** - Complete and return the above registration form via post or email, together with your cheque payable to Virtue Insight.

#### By Bank Transfer:

Account Name - Virtue Insight  
Account Type - Current  
Account Number - 915020031763553  
Bank Name - Axis Bank  
Bank Address - 2/8 LAMBERT NAGAR, 1st cross street,  
Virugambakkam, Chennai - 600 092  
Branch Name - Virugambakkam, Chennai  
Swift Code - AXISINBB211  
NEFT / IFSC Code - UTIB0000211  
Micro Code - 600211010

### Queries:

Should you have any questions on bookings, Please feel free to contact us.

Email: [info@virtueinsight.com](mailto:info@virtueinsight.com)  
Web: <http://www.virtueinsight.com>  
India Office: Tel: +91 44 42108101  
UK Office: Tel: +44 - 2036120886

### General Information Venue:

Kohinoor Continental Hotel  
Andheri Kurla Road  
Andheri ( E )  
Mumbai 400059 - India  
Tel: 91 22 66919000 / 91 22 28209999

### TERMS AND CONDITIONS:

**Payment terms:** Virtue Insight requires the full amount to be paid before the conference. We may refuse entry to delegates who have not paid their invoice in full.

**Cancellations:** Delegates and vendors are subject to the following charges and refunds upon withdrawal or cancellation between 2-3 month's prior 75% cancellation fee/ 25% refund. Less than 2 months prior to the event Full cancellation fee / No refund.

**Administration Fee:** If you cancel your participation (once confirmed) and haven't paid the attendance fee you will be liable to pay an administration fee of INR 5,000

**Substitutions/Name Change:** If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. This can be done at no extra cost.

**Presentation:** If you cannot attend the conference, you can still purchase the presentations for INR 5,000 + Tax

**Indemnity:** Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will reschedule the event.

**Fee:** The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation.

## VENUE

Kohinoor Continental Hotel

Address: Andheri Kurla Road,  
Andheri ( E ),  
Mumbai - 400059,  
India.



## MAP & DIRECTIONS

Organized by



Plot No - 07 - 2nd Floor  
Ekambaram Industrial Estate  
Alapakkam, Porur  
Chennai - 600 116  
India

+91 44 42108101

[info@virtueinsight.com](mailto:info@virtueinsight.com)